American Journal of Ophthalmology
Volume 135, Issue 1 , Pages 55-63 , January 2003

A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma

  • Robert S. Noecker, MD

      Affiliations

    • University of Arizona (R.S.N.), Tucson, Arizona, USA
    • Corresponding Author InformationInquiries to Scott M. Whitcup, MD, 2525 Dupont Dr, Irvine, CA, 92612-1599 USA; fax: (714) 246-6756;
    • ,
  • Monte S. Dirks, MD

      Affiliations

    • Black Hills Regional Eye Institute (M.S.D.), Rapid City, South Dakota, USA
    • ,
  • Neil T. Choplin, MD

      Affiliations

    • Eye Care of San Diego (N.T.C.), San Diego, California, USA
    • ,
  • Paula Bernstein, MS

      Affiliations

    • Allergan, Inc. (P.B., A.L.B., S.M.W.), Irvine, California, USA
    • ,
  • Amy L. Batoosingh

      Affiliations

    • Allergan, Inc. (P.B., A.L.B., S.M.W.), Irvine, California, USA
    • ,
  • Scott M. Whitcup, MD

      Affiliations

    • Allergan, Inc. (P.B., A.L.B., S.M.W.), Irvine, California, USA
    • ,
  • The Bimatoprost/Latanoprost Study Group

,Accepted 19 August 2002.

References 

  1. The advanced glaucoma intervention study (AGIS) 7 (the relationship between control of intraocular pressure and visual field deterioration). Am J Ophthalmol. 2000;130:429–440
  2. Kass M, Heuer D, Higginbotham E, et al.  The ocular hypertension treatment study (a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma). Arch Ophthalmol. 2002;120:701–713
  3. Brandt J, VanDenburgh A, Chen K, Whitcup S  Bimatoprost Study Group . Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP (a 3-month clinical trial). Ophthalmology. 2001;108:1023–1031
  4. Sherwood M, Brandt J  Bimatoprost Study Groups . 1 + 2. 6-Month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated IOP. Surv Ophthalmol. 2001;45(Suppl 4):S361–S368
  5. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning (a comparison with timolol. Scandinavian Latanoprost Study Group). Ophthalmology. 1995;102:1743–1752
  6. Camras C. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma (a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group). Ophthalmology. 1996;103:138–147
  7. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996;103:126–137
  8. DuBiner H, Cooke D, Dirks M, et al.  Efficacy and safety of bimatoprost in patients with elevated IOP (a 30-day compar-ison with latanoprost). Surv Ophthalmol. 2001;45(Suppl 4):S353–S360
  9. Gandolfi S, Simmons S, Sturm R, Chen K, VanDenburgh A. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. The Bimatoprost Study Group 3. Adv Ther. 2001;18:110–121
  10. Morikawa T, Yoshida M. A useful testing strategy in phase III trials (combined test of superiority and test of equivalence). J Biopharm Stat. 1995;5:297–306
  11. In:  Fleiss J editors. Statistical methods for rates and proportions. New York: John Wiley and Sons; 1981;
  12. In:  Lehmann E editors. Nonparametrics. Statistical methods based on ranks. California: Holden-Day; 1975;
  13. Singh K, Spaeth G, Zimmerman T, Minckler D. Target pressure? Glaucomatologists’ holey grail. Ophthalmology. 2000;107:629–630
  14. Mao L, Stewart W, Shields M. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 1991;111:51–55
  15. Nordmann J, Mertz B, Yannoulis N, et al.  A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension (6 month data). Am J Ophthalmol. 2002;133:1–10
  16. Simmons S, Samuelson T. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma (Alphagan/Xalatan Study Group). Clin Ther. 2000;22:388–399
  17. Alm A, Widengard I, Kjellgren D, et al.  Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995;79:12–16

☆ This study was supported by Allergan, Inc. Paula Bernstein, Amy L. Batoosingh, and Scott M. Whitcup are employees of Allergan, Inc.InternetAdvance publication at ajo.com Oct 1, 2002.

PII: S0002-9394(02)01827-5

American Journal of Ophthalmology
Volume 135, Issue 1 , Pages 55-63 , January 2003

Article Tools

* Image Usage & Resolution